VV-ECMO May Bridge Recovery for Patients With Hematologic Malignancies

VV-ECMO May Bridge Recovery for Patients With Hematologic Malignancies

While VV-ECMO has historically been linked to poor outcomes for patients with active hematological malignancies, emerging evidence suggests potential benefits for specific candidates. The report details the treatment of a 19-year-old male diagnosed with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma, a rare and aggressive peripheral T-cell lymphoma that is typically identified at advanced stages.

Clinical Progression and Intervention

The patient’s medical trajectory began with a four-day hospitalization for pleuritic chest pain and fever, resulting in a diagnosis of acute pericarditis and discharge. However, the patient was readmitted a few days later after developing newly developed lymphadenopathies and acute respiratory failure. At the time of readmission, he was diagnosed with nosocomial pneumonia.

Despite the administration of broad-spectrum antibiotics, the patient’s condition deteriorated. This decline necessitated the use of mechanical ventilation and VV-ECMO to manage refractory hypoxemia. Following these interventions, further investigation confirmed the diagnosis of ALK-positive anaplastic large cell lymphoma with pulmonary involvement.

Treatment and Recovery Outcomes

The patient underwent a chemotherapy regimen consisting of prednisolone, etoposide, vincristine, doxorubicin, and cyclophosphamide (CHOEP). This treatment led to significant clinical improvement, which subsequently allowed for the successful weaning of the VV-ECMO support.

Laboratory data from the patient’s emergency department admissions showed a decline in hemoglobin from 11.2 g/dL during the first admission to 9.8 g/dL during the second. His white blood cell count increased from 16.5 × 10⁹/µL to 20.0 × 10⁹/µL, with neutrophils rising from 12.5 × 10⁹/µL to 16.0 × 10⁹/µL between the two admissions.

The Role of ECMO in Critical Care

ECMO is an advanced form of life support that utilizes a specialized heart-lung machine to oxygenate blood outside the body, providing the heart and lungs time to recover. While originally created for children and infants with severe respiratory illnesses, the technology is now used for adults and infants experiencing acute respiratory or cardiac failure, and can act as a bridge to lung or heart transplantation.

The utility of specific ECMO positioning is also a subject of ongoing study. A study involving 170 patients with severe acute respiratory distress syndrome (ARDS), primarily related to COVID-19, found that prone positioning did not significantly reduce the time to successful VV-ECMO weaning when compared to supine positioning.

Institutional Standards of Excellence

The complexity of these procedures requires high standards of care. The Extracorporeal Life Support Organization (ELSO), an international nonprofit consortium, manages a Center of Excellence program to recognize hospitals maintaining top standards in safety, training, and quality.

For example, the UNC ECMO Program was awarded the Platinum Level Center of Excellence designation, the highest distinction from ELSO, placing the program in the top 5% of such programs globally. This designation, effective from January 1, 2027, through December 31, 2029, recognizes exceptional performance in clinical outcomes, staff education, and evidence-based care.